SenFlag Signature Reliably Spots Senescent Cells Across Mouse and Human Tissues
A new gene signature called SenFlag precisely identifies senescent cells in single-cell data, tracking their accumulation with age and injury.
Zusammenfassung
Scientists have developed SenFlag, a streamlined gene signature that accurately identifies senescent cells — aging, dysfunctional cells linked to tissue decline and disease — in both mouse and human tissues. Unlike previous methods hampered by cellular noise, SenFlag captures a conserved set of molecular markers: reduced activity in genes driving cell division and chromatin organization, alongside elevated cell-cycle brakes and lysosomal activity. Applied to single-cell RNA-sequencing datasets, SenFlag detects a rare but steadily growing population of senescent cells that concentrates in epithelial and endothelial tissues, increases with age and tissue injury, and decreases when senescence-targeting treatments are applied. This tool should sharpen research into how senescent cells drive aging and disease.
Detaillierte Zusammenfassung
Cellular senescence — the process by which damaged or stressed cells stop dividing but resist death — plays a central role in aging, wound healing, and disease. Yet identifying these cells precisely in complex tissues has been difficult because senescent cells share features with other cell states and occur at low frequency. A reliable molecular signature is urgently needed to accelerate research and drug development targeting senescent cells.
Researchers at the European Research Institute for the Biology of Ageing (ERIBA) developed SenFlag, a curated gene signature derived by systematically analyzing bulk and single-cell RNA-sequencing data across multiple senescence models. Rather than relying on any single marker, SenFlag integrates a conserved transcriptional program: reduced expression of proliferation and chromatin genes (including HMGB1/2 and HMGN2), upregulation of well-known cell-cycle inhibitors CDKN1A and CDKN2A, increased CCND1 expression, and elevated lysosomal markers including V-ATPase subunits and cathepsins.
When applied to in vivo datasets from mice and humans, SenFlag identified a rare but progressively accumulating senescent cell population. These cells were enriched in epithelial and endothelial compartments and increased in abundance with advancing age and following tissue injury — two hallmarks of biological senescence. Crucially, SenFlag-positive cells were reduced in datasets where senescence-clearing (senolytic) interventions had been applied, strongly supporting the signature's specificity.
The clinical implications are significant. SenFlag provides a standardized, interpretable tool for mapping senescent cell burden across tissues, age groups, and disease states. This could help identify which tissues accumulate the most senescent cells and guide the development and evaluation of senolytic therapies.
Key caveats include that the full study is not yet openly available, so this summary relies on the abstract alone. Additionally, the lead author's institution has commercial ties to senolytic biotech companies, which warrants attention when interpreting claims about therapeutic relevance.
Wichtigste Erkenntnisse
- SenFlag integrates proliferation, chromatin, cell-cycle, and lysosomal markers to identify senescent cells more accurately than prior methods.
- Senescent cells detected by SenFlag accumulate progressively with age and following tissue injury in both mice and humans.
- SenFlag-positive cells are enriched in epithelial and endothelial tissue compartments across species.
- Senolytic interventions reduce SenFlag-positive cell counts in datasets, validating the signature's in vivo specificity.
- HMGB1/2, HMGN2, CDKN1A, CDKN2A, CCND1, V-ATPase subunits, and cathepsins form the core of the conserved signature.
Methodik
SenFlag was derived through systematic analysis of bulk and single-cell RNA-sequencing datasets spanning multiple senescence induction models. The signature was then validated in vivo by applying it to aging, injury, and senolytic intervention datasets in both mouse and human tissues.
Studienlimitierungen
This summary is based on the abstract only, as the full paper is not open access. The lead author has disclosed board membership and equity relationships with multiple senolytic biotechnology companies, which represents a potential conflict of interest. Prospective clinical validation of SenFlag as a biomarker in patient cohorts has not yet been reported.
Hat dir diese Zusammenfassung gefallen?
Erhalte die neueste Longevity-Forschung jede Woche in deinen Posteingang.
E-Mail-Adresse zum Abonnieren eingeben: